XXXX in a Special Operations Candidate: Case Report and Review of the Literature.

@entity1 @entity31949 @entity12437 @entity344 @entity755 @entity20136 @entity74
BACKGROUND: A 19-year-old male military recruit who presented for a screening physical for US Naval Special Warfare Duty was found to have @entity31949 . Medical history revealed mildly increased frequency of bowel movements, but was otherwise unremarkable. His presentation was most consistent with heterozygous @entity20136 ( @entity20136 ), and the @entity1 was cleared for Special Operations duty. METHODS: A literature search was conducted using PubMed/MEDLINE. Keywords included @entity20136 , heterozygous @entity20136 , @entity12437 , @entity31949 , diving, special operations, and military. Results that included cases of @entity20136 were included. RESULTS: Review of the literature reveals that @entity20136 is a @entity74 frequently, but not always, due to a mutation in the @entity755 ( @entity755 ) gene. Those with the condition should be screened for ophthalmologic, neurologic, and @entity344 . Analysis of the disease, as well as the absence of reported cases of @entity20136 in diving and Special Operations, suggest there is minimal increased risk in diving and Special Operations for @entity1 who are likely heterozygous, are asymptomatic, and have a negative workup for potential complications from the disease. CONCLUSION: Individuals with presumed or proven heterozygous @entity20136 seeking clearance for Special Operations duty should be given precautions, undergo careful questioning for history of disease-specific complications, and should have a baseline evaluation. If negative, it seems reasonable to clear the @entity1 for Special Operations and diving.
